Drug Profile


Alternative Names: ARENEGYR; CNGRC peptide-TNF alpha conjugate; NGR-hTNF; NGR-TNFα

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Scientific Institute San Raffaele
  • Developer European Organisation for Research and Treatment of Cancer; MolMed; Scientific Institute San Raffaele
  • Class Antineoplastics; Blood proteins; Glycoproteins; Monokines; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Capillary permeability modulators; CD13 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Mesothelioma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Mesothelioma
  • Phase II Colorectal cancer; Hepatocellular carcinoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma
  • Phase I Solid tumours

Most Recent Events

  • 23 Dec 2016 The EMA validates the submission of Conditional Marketing Authorisation application for NGR-TNF for Mesothelioma
  • 06 Dec 2016 Preregistration for Mesothelioma (Combination therapy, Second-line therapy or greater, Late-stage disease) in European Union (IV)
  • 26 Jan 2016 MolMed completes a phase II trial in Ovarian cancer (combination therapy, late-stage disease, second-line therapy or greater) in Italy (IV) (EudraCT2012-005745-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top